EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Comparisons

What is the best GLP-1 procurement approach for a growing clinic?

Dose Diligence research deskSection 03 · Page 1 of 12Last updated 17 Nov 2026

Our recommendation is to compare approved-medicine dispensing arrangements first, establish a tested alternative fulfilment route, and evaluate clinic-stock purchasing only where the clinic has a specific operational reason to own inventory. Keep proposed compounding arrangements outside the commercial shortlist until clinical, legal and quality reviews establish their suitability.

This is a procurement recommendation—not a claim that one medicine or named pharmacy is best for every patient. FDA advises that compounded GLP-1 drugs should be used only when a patient's medical needs cannot be met by an FDA-approved drug. Compounded products do not undergo FDA's premarket review for safety, effectiveness and quality. (fda.gov)

For the procurement committee, three questions should precede any price comparison:

  1. What are we buying? Medicine inventory, dispensing services, prescription-routing technology, or assistance accessing a patient programme?
  2. Whose expenditure can we influence? The clinic's, the patient's, or an insurer's?
  3. What evidence supports this exact arrangement? Product, presentation, dispensing facility, destination state, payment route and intended use—not simply the supplier's brand name.

Evidence standard: Regulatory and programme facts below are sourced. Fit assessments, suggested contract terms, score weights and implementation steps are analyst recommendations. Public programme prices are not negotiated clinic quotations; no supplier's capacity, service performance or legal suitability has been independently audited for this report.

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Section sources →